Literature DB >> 15481631

Platelet activation in heart failure.

Andreas Schäfer1, Martin Eigenthaler, Johann Bauersachs.   

Abstract

Heart failure is a common disease in aging western populations. Not only severe but even mild to moderate heart failure is associated with increasing risk for stroke. This can partly be attributed to concomitant atrial fibrillation, a well-known risk factor for stroke. Furthermore, the increased risk for thromboembolic events in congestive heart failure has been attributed to a hypercoagulable state including formation of intraventricular thrombi. However, more recently, enhanced platelet activation has been described in patients with heart failure in sinus rhythm. Vascular endothelial dysfunction and reduced formation of the platelet inhibitor nitric oxide appear to contribute to platelet activation in heart failure. This review article summarizes the historical knowledge of abnormal platelet function in heart failure, focuses on pathophysiological changes in heart failure which could influence platelet activation, and discusses drug regimens investigated in heart failure to reduce platelet activation either by direct anti-platelet effects or by modulating the release of platelet inhibiting substances.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15481631

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

1.  Longitudinal assessment of the platelet transcriptome in advanced heart failure patients following mechanical unloading.

Authors:  Callie Frey; Antigoni G Koliopoulou; Emilie Montenont; Neal D Tolley; Hadi Javan; Stephen H McKellar; Stavros G Drakos; Craig H Selzman; Matthew T Rondina
Journal:  Platelets       Date:  2020-01-14       Impact factor: 3.862

2.  Clopidogrel-induced neutropenia after coronary stenting: is cilostazol a good alternative?

Authors:  Massimo Montalto; Italo Porto; Antonella Gallo; Claudia Camaioni; Roberta Della Bona; Antonio Grieco; Filippo Crea; Raffaele Landolfi
Journal:  Int J Vasc Med       Date:  2011-08-11

Review 3.  Platelets: still a therapeutical target for haemostatic disorders.

Authors:  Reinaldo Barros Geraldo; Plínio Cunha Sathler; André Luiz Lourenço; Max Seidy Saito; Lucio M Cabral; Pabulo Henrique Rampelotto; Helena Carla Castro
Journal:  Int J Mol Sci       Date:  2014-10-07       Impact factor: 5.923

4.  First approach to distinguish between cardiac and arteriosclerotic emboli of individual stroke patients applying the histological THROMBEX-classification rule.

Authors:  Florian C Roessler; Nicolas Kalms; Florian Jann; Andrè Kemmling; Julika Ribbat-Idel; Florian Stellmacher; Inke R König; Marcus Ohlrich; Georg Royl
Journal:  Sci Rep       Date:  2021-04-19       Impact factor: 4.379

5.  Combining patient proteomics and in vitro cardiomyocyte phenotype testing to identify potential mediators of heart failure with preserved ejection fraction.

Authors:  Roseanne Raphael; Diana Purushotham; Courtney Gastonguay; Marla A Chesnik; Wai-Meng Kwok; Hsiang-En Wu; Sanjiv J Shah; Shama P Mirza; Jennifer L Strande
Journal:  J Transl Med       Date:  2016-01-20       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.